A new clinical study is drawing attention to the possibility of treating HER2-positive breast cancer before surgery with a next-generation antibody designed to attack the cancer-driving receptor in two different ways. Published in Nature Communications in 2026, the NeoZanHER phase 2 trial evaluates zanidatamab in patients with early-stage HER2-positive breast cancer. The study, led by Valero, Pohlmann, Mouabbi and colleagues, is described as a single-arm, open-label investigation, placing it within a rapidly expanding effort to improve outcomes before a tumor is removed rather than waiting until after surgery to assess how it responds.
HER2, or human epidermal growth factor receptor 2, is a protein found on the surface of cells. In some breast cancers, the HER2 gene is amplified, causing cells to produce excessive amounts of the receptor. This abnormal signaling can stimulate continuous cell division and tumor growth. HER2-positive disease was once associated with particularly aggressive clinical behavior, but targeted medicines have transformed its treatment. Drugs such as trastuzumab and pertuzumab block HER2-related signaling and can recruit immune cells to destroy cancer cells. Zanidatamab belongs to the same broad family of HER2-directed therapies, but its molecular design is intended to engage two separate regions of HER2 simultaneously.
Zanidatamab is a biparatopic antibody, meaning that it binds to two distinct epitopes, or molecular sites, on the HER2 receptor. This dual engagement may interfere with HER2 biology more extensively than an antibody that attaches to only one site. The antibody can promote receptor clustering at the cell surface, a process that may encourage the cancer cell to internalize and remove HER2 from its membrane. It can also inhibit downstream growth signals and stimulate antibody-dependent cellular cytotoxicity, in which immune cells recognize the antibody-coated tumor cell and help destroy it. These mechanisms are being investigated as a way to produce deeper tumor responses while addressing some forms of resistance to established HER2 therapies.
The NeoZanHER study focuses on early-stage disease, a setting in which treatment is often given before surgery. This approach is known as neoadjuvant therapy. Rather than treating an unseen residual risk after an operation, clinicians can observe how a tumor responds while it remains in the breast and lymph nodes. Imaging can show changes in tumor size, while tissue removed during surgery can reveal whether invasive cancer remains. When no invasive cancer is detected in the breast and sampled lymph nodes at surgery, the result is called a pathologic complete response. In HER2-positive breast cancer, this measure is widely used as an early indicator of treatment activity and may help guide the intensity of subsequent therapy.
The trial’s single-arm design means that participants receive the investigational treatment without being randomly assigned to a comparison group within the study. This structure can provide an early view of feasibility, safety and antitumor activity, particularly when researchers are evaluating a treatment strategy in a defined patient population. However, a single-arm phase 2 trial cannot establish superiority over standard therapy on its own. Any apparent benefit must be interpreted alongside historical results, differences in patient selection and the length of follow-up. Randomized trials remain essential for determining whether a new regimen improves long-term outcomes such as recurrence-free survival and overall survival.
The open-label nature of NeoZanHER means that both investigators and participants know which treatment is being administered. While this design can simplify clinical management and allow researchers to document treatment effects in real time, it can also introduce sources of bias in subjective assessments. For this reason, the most informative endpoints are generally those supported by pathology, imaging protocols, laboratory measurements and carefully defined safety criteria. In a neoadjuvant trial, researchers may also examine biomarkers in tumor tissue and blood to understand why some cancers respond while others continue to grow despite HER2 blockade.
The biological question behind the study is particularly important because HER2-positive breast cancer is not a single uniform disease. Tumors can differ in the level of HER2 expression, the presence of hormone receptors, their immune-cell environment and the genetic pathways that operate downstream of HER2. Some tumors may initially shrink but retain microscopic resistant cells capable of causing relapse later. A dual-epitope antibody such as zanidatamab could, in theory, provide broader receptor suppression and more effective immune engagement, but the clinical value of that strategy depends on measurable patient outcomes and a manageable safety profile. The study therefore matters not simply because it tests a new drug, but because it explores whether molecular precision can translate into better preoperative cancer control.
The timing of the research also reflects a major shift in breast cancer treatment. Modern care increasingly combines surgery, chemotherapy, targeted antibodies, antibody-drug conjugates and immunotherapy according to tumor biology. In this landscape, a response achieved before surgery can influence decisions after surgery. Patients with a strong response may be managed differently from those with residual disease, who may require additional treatment aimed at eliminating resistant cancer cells. This response-adapted model seeks to avoid both undertreatment and unnecessary exposure to toxic therapies, although its success depends on reliable biomarkers and evidence that early response accurately predicts long-term protection from relapse.
The NeoZanHER report is therefore likely to be followed closely by oncologists and researchers seeking alternatives or refinements to established HER2-directed regimens. The citation identifies the work as a phase 2, single-arm, open-label trial, but the bibliographic information alone does not provide the study’s participant number, treatment schedule, response rates, adverse-event profile or survival results. Those details are essential for judging the clinical significance of the findings. Until they are examined in the full publication and confirmed in larger comparative studies, zanidatamab should be viewed as an investigational approach in this setting rather than a replacement for standard treatment.
What makes the study newsworthy is the possibility that a carefully engineered antibody could reshape the earliest stage of treatment for a biologically aggressive cancer. If future evidence shows that dual-site HER2 targeting produces high rates of complete tumor eradication before surgery without adding unacceptable heart, blood or infusion-related complications, it could become part of a more personalized treatment strategy. For now, NeoZanHER represents an important test of that hypothesis: whether attacking the same cancer receptor through complementary molecular mechanisms can deliver a deeper and more durable response when treatment begins at the moment the disease is still potentially curable.
Subject of Research: Zanidatamab as neoadjuvant therapy for patients with early-stage HER2-positive breast cancer.
Article Title: Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.
Article References: Valero, V., Pohlmann, P.R., Mouabbi, J. et al. “Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76662-6
Image Credits: AI Generated
DOI: 10.1038/s41467-026-76662-6
Keywords: zanidatamab, HER2-positive breast cancer, early-stage breast cancer, neoadjuvant therapy, targeted therapy, biparatopic antibody, NeoZanHER, oncology, precision medicine, clinical trial
